Coping with motor neurone disease — an analysis using self-regulation theory

1993 ◽  
Vol 7 (4_suppl) ◽  
pp. 21-30 ◽  
Author(s):  
Louise Earll ◽  
Marie Johnston ◽  
Elspeth Mitchell
Keyword(s):  
Chronic Disease ◽  
Environmental Changes ◽  
Self Regulation ◽  
Motor Neurone ◽  
Motor Neurone Disease ◽  
Theoretical Approaches ◽  
High Prevalence ◽  
And Control ◽  
To Receive

Medicine and environmental changes have had tremendous success in controlling the infectious diseases that were the major causes of death in the last century. However, the consequential extension of life has been accompanied by an increase in the number of persons living with and dying of chronic illness.1 Despite these changes and their implications, the means by which people cope with such illnesses has only recently begun to receive the attention the subject warrants. 2,3 Such diseases have a high prevalence in the population and self-detection and self-management are critical to the treatment and control of chronic disease and disability.4 This paper examines how people cope with motor neurone disease and sets this in the context of earlier research on psychological aspects of chronic disease and current theoretical approaches to coping with long-term ill health.

Ageing, multimorbidity, and daily functioning

2017 ◽  
pp. 111-116
Author(s):  
Barbara Gryglewska ◽  
Karolina Piotrowicz ◽  
Tomasz Grodzicki
Keyword(s):  
Risk Factor ◽  
Chronic Disease ◽  
Functional Performance ◽  
Negative Impact ◽  
High Prevalence ◽  
Short And Long Term ◽  
Long Term Prognosis ◽  
Clinical Measures

Multimorbidity is defined as any combination of a chronic disease with at least one other acute or chronic disease or biopsychosocial or somatic risk factor. Old age is a leading risk factor for multimorbidity. It has a negative impact on short- and long-term prognosis, patients’ cognitive and functional performance, self-care, independence, and quality of life. It substantially influences patients’ clinical management and increases healthcare-related costs. There is a great variety of clinical measures to assess multimorbidity; some are presented in this chapter. Despite its high prevalence in older adults, clinical guidelines for physicians managing patients with multimorbidity are underdeveloped and insufficient.

Comparison of faecal microbe diversity between motor neurone disease (mnd) and control participants

2017 ◽  
Vol 88 (5) ◽  
pp. e1.83-e1
Author(s):  
Frederik J Steyn ◽  
Restuadi Restuadi ◽  
Zara Ioannides ◽  
Shyuan T Ngo ◽  
Allan McRae ◽  
...  
Keyword(s):  
Motor Neurone ◽  
Motor Neurone Disease ◽  
Microbe Diversity ◽  
And Control

Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 2013-2013
Author(s):  
Marta Domenech ◽  
Carles Fabregat-Franco ◽  
Carlos Mesia ◽  
Anna Esteve ◽  
Sonia Del Barco Berron ◽  
...  
Keyword(s):  
Methylation Status ◽  
Progression Free Survival ◽  
Long Term Results ◽  
Control Group ◽  
Measurable Disease ◽  
Previously Treated ◽  
And Control ◽  
To Receive

2013 Background: We previously presented our results of the GEINO 1401 trial that randomized patients diagnosed with glioblastoma and treated with chemoradiotherapy and adjuvant temozolomide (TMZ) followed by six cycles of TMZ, to receive an extended use of TMZ up to 12 cycles or to control. We found no differences in 6-months neither progression free survival (PFS) nor overall survival (OS). In this report we actualize our results and analyse long-term survivor patients (LTSP). Methods: The trial NCT02209948 randomized (ratio 1:1) 159 patients diagnosed with glioblastoma who had been treated with standard therapy to stop treatment or to continue up to 12 cycles of TMZ. Patients were stratified based on their O6-methylguanine-DNA-methyltransferasa (MGMT) methylation status and presence or absence of measurable disease at inclusion. We update here OS outcomes and analyse the data of LTSP defined as an OS over 30 months from diagnosis. Results: At a median follow-up of 20 months, 82.4% of the patients had died and 89.9% had progressed. The median OS from randomization was 22.0 months for the control arm and 18.2 for the experimental arm: HR 0.957 (95%CI 0.806-1.136, p = 0.615). At 2 years from randomization there were a 61% of survivors in the TMZ group and 62% in the control group. There were a 49.7% of LTSP showing no differences between TMZ and control group. We found a higher prevalence of methylated MGMT in LTSP, but no differences were shown in patients with or without measurable disease at inclusion, status of IDH and the use of bevacizumab after progression. Conclusions: Adding 6 cycles of TMZ after the first 6 adjuvant cycles confers no additional benefit in OS. Nearly 50% of the patients included in GEINO 1401 who had been previously treated with TMZ 6 cycles without progressing were LTSP. Clinical trial information: NCT02209948.

Rheumatic fever

1999 ◽  
Vol 9 (3) ◽  
pp. 239-248 ◽  
Author(s):  
Cleonice de Carvalho Coelho Mota ◽  
Zilda Maria Alves Meira
Keyword(s):  
Rheumatic Fever ◽  
Cardiac Involvement ◽  
Unsolved Problem ◽  
Developed Countries ◽  
Industrialized Countries ◽  
Complete Understanding ◽  
High Prevalence ◽  
Children And Young Adults ◽  
And Control

AbstractIn recent years, rheumatic fever has been declining in the industrialized countries, and has became a rare disease. In developing areas, nonetheless, the sequels of its cardiac involvement have important implications from the stance of public health, and this disease is still the main cause of heart disease in children and young adults. From a historical perspective, the long-term prevention and the control of socioeconomic problems have been proven to be effective, and it is these measures which have contributed to the decline of the disease in developed countries. But, due to its present high prevalence around the world, and the potential for his resurgence, this disease remains an unsolved problem. Furthermore, the complete understanding of its pathophysiology remains a challenge. In this presentation, we will discuss our experience with epidemiological, clinical and prophylatic aspects of this enigmatic disease, and the strategies we have developed to study and control heumatic fever in Minas Gerais, Brazil.

scholarly journals Classification of Actigraphy Records from Bipolar Disorder Patients Using Slope Entropy: A Feasibility Study

Entropy ◽  
2020 ◽  
Vol 22 (11) ◽  
pp. 1243
Author(s):  
David Cuesta-Frau ◽  
Jakub Schneider ◽  
Eduard Bakštein ◽  
Pavel Vostatek ◽  
Filip Spaniel ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Continuous Monitoring ◽  
Monitoring And Control ◽  
Term Evolution ◽  
Entropy Measures ◽  
High Prevalence ◽  
Technological Developments ◽  
And Control

Bipolar Disorder (BD) is an illness with high prevalence and a huge social and economic impact. It is recurrent, with a long-term evolution in most cases. Early treatment and continuous monitoring have proven to be very effective in mitigating the causes and consequences of BD. However, no tools are currently available for a massive and semi-automatic BD patient monitoring and control. Taking advantage of recent technological developments in the field of wearables, this paper studies the feasibility of a BD episodes classification analysis while using entropy measures, an approach successfully applied in a myriad of other physiological frameworks. This is a very difficult task, since actigraphy records are highly non-stationary and corrupted with artifacts (no activity). The method devised uses a preprocessing stage to extract epochs of activity, and then applies a quantification measure, Slope Entropy, recently proposed, which outperforms the most common entropy measures used in biomedical time series. The results confirm the feasibility of the approach proposed, since the three states that are involved in BD, depression, mania, and remission, can be significantly distinguished.

scholarly journals Systematic review and meta analysis of differential attrition between active and control arms in randomized controlled trials of lifestyle interventions in chronic disease

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Bevens W ◽  
Shoushtari A ◽  
Jelinek P ◽  
Jelinek GA ◽  
Weiland TJ
Keyword(s):  
Systematic Review ◽  
Chronic Disease ◽  
Chronic Diseases ◽  
Lifestyle Intervention ◽  
Meta Analysis ◽  
Research Question ◽  
Lifestyle Interventions ◽  
And Control

Abstract Background Attrition is a major obstacle for lifestyle interventions sustained for the medium-to-long term and can have significant consequences on the internal validity of a trial. When the degree of attrition differs between active and control arms this is termed differential attrition and is an important consideration during initial stages of trial planning. Objectives The primary research question of this study was: what is the differential attrition between treatment arms in lifestyle interventions for prevalent chronic diseases? Methods We performed a systematic review and meta-analysis of 23 studies involving a lifestyle intervention component in cohorts with chronic diseases. The search accessed three databases: Scopus, Medline Ovid and Web of Science. Attrition between treatment arms was analysed using a random-effects model and examined the relationship between the relative attrition and potential moderators, such as time to final follow-up, time to first follow-up, type of disease, type of control, type of intervention and length of treatment. Results The pooled risk ratio was 1.00 (95% CI 0.97 – 1.03) and only one study fell outside this range. A univariable association was described between the pooled risk ration and length (years) to final follow-up, which did not remain in the multivariable model. Conclusions Ultimately, we found no evidence of differential attrition in medium-to-long term lifestyle intervention studies for chronic disease, increasing confidence in conducting such studies with minimal potential of attrition bias. Trial registration PROSPERO registration number CRD42018084495.

Sign in / Sign up

Export Citation Format

Share Document